A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons - Full Text View

Sponsor:	Otsuka America Pharmaceutical
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002130

Purpose

To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.

Condition	Intervention
HIV Infections	Drug: Vesnarinone

Study Type:	Interventional
Study Design:	Treatment, Open Label, Safety Study
Official Title:	A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Vesnarinone

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Detailed Description:

Patients who have completed a limited duration study (less than 12 months of continuous treatment) of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their regimen of vesnarinone for 12 months beyond their original participation.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.
Acyclovir for acute treatment of herpes.

Exclusion Criteria

Concurrent Medication:

Excluded:

Antiretroviral agents, including ddI, ddC, AZT, and d4T.
Immunosuppressive agents.
Investigational HIV drugs/therapies including vaccines.
Interferon or other immunomodulating agents.
Corticosteroids (other than topical).
Megestrol acetate.
Agents known to cause neutropenia.
Ganciclovir.
Cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

Radiation therapy.

Patients with the following prior conditions are excluded:

Poor compliance (less than 80 percent of drug taken) on the Phase I protocol (FDA 234A or FDA 234B).
Missed more than one clinic visit on the Phase I protocol.

Prior Medication:

Excluded:

Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.

Patients meet the following criteria:

Successful completion of short-term therapy with vesnarinone on FDA 234A or FDA 234B.

Active illicit drug abuse.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002130

Locations

United States, California
UCLA School of Medicine
Los Angeles, California, United States, 900121973
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308

Sponsors and Collaborators

Otsuka America Pharmaceutical

More Information

No publications provided

Study ID Numbers:	234C, 22-93-253
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002130 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Acquired Immunodeficiency Syndrome
Antiviral Agents
vesnarinone

Additional relevant MeSH terms:

Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antineoplastic Agents
Cardiotonic Agents
Physiological Effects of Drugs
Infection
Therapeutic Uses
Retroviridae Infections
RNA Virus Infections
Immune System Diseases
Acquired Immunodeficiency Syndrome

Adjuvants, Immunologic
Enzyme Inhibitors
Cardiovascular Agents
Protective Agents
Antiviral Agents
Immunologic Deficiency Syndromes
Pharmacologic Actions
Virus Diseases
Phosphodiesterase Inhibitors
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections
Vesnarinone

ClinicalTrials.gov processed this record on November 22, 2009